Scribe Therapeutics (SCTX) Stock Overview

A clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. More details

SCTX fundamental analysis
Snowflake Score
Valuation	2/6
Future Growth	0/6
Past Performance	0/6
Financial Health	2/6
Dividends	0/6

Rewards

Revenue grew by 9% over the past year

Risk Analysis

Negative shareholders equity

Shares are highly illiquid

Less than 3 years of financial data is available

SCTX Community Fair Values

Create Narrative

See what others think this stock is worth. Follow their fair value or set your own to get alerts.

NEW480,485 members

Join community and earn perks

Gain real feedbackFrom our editorial team, personally. Not silence.

Grow your followingReal investors. The kind who actually invest, not scroll past.

Unlock free accessFree premium subscription for consistent and quality authors.

Learn more Create Narrative

480,485 investors already sharing narratives

View all narratives

Scribe Therapeutics Inc. Competitors

Price History & Performance

Summary of share price highs, lows and changes for Scribe Therapeutics
Historical stock prices
Current Share Price	US$14.00
52 Week High	US$0
52 Week Low	US$0
Beta	0
1 Month Change	n/a
3 Month Change	n/a
1 Year Change	n/a
3 Year Change	n/a
5 Year Change	n/a
Change since IPO	0%

Recent updates

Shareholder Returns

	SCTX	US Biotechs	US Market
7D	n/a	-0.5%	-2.0%
1Y	n/a	29.7%	15.1%

Return vs Industry: Insufficient data to determine how SCTX performed against the US Biotechs industry.

Return vs Market: Insufficient data to determine how SCTX performed against the US Market.

Price Volatility

Is SCTX's price volatile compared to industry and market?
SCTX volatility
SCTX Average Weekly Movement	n/a
Biotechs Industry Average Movement	10.1%
Market Average Movement	7.1%
10% most volatile stocks in US Market	16.1%
10% least volatile stocks in US Market	3.2%

Stable Share Price: SCTX's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: Insufficient data to determine SCTX's volatility change over the past year.

About the Company

Founded	Employees	CEO	Website
2017	89	Benjamin Oakes	www.scribetx.com

Scribe Therapeutics Inc. is a clinical-stage biotechnology company, focuses on research and developing genetic medicines using CRISPR-based tools to address the root cause of diseases, with a primary focus on cardiometabolic conditions in the United States. The company offers STX-1150 designed to be a single-course in vivo epigenetic silencing treatment targeting the PCSK9 gene; STX-1200 is CRISPR-based gene editing program that aims to offer a permanent solution for patients with elevated Lp(a); and STX-1400 is designed to target and remove the transcriptional start site of the APOC3 gene and strongly reduce mRNA expression. It uses CRISPR-based platforms, such as ELXR, designed for precise, durable epigenetic silencing of genes without changing the underlying DNA sequence; and XE, designed to support specific and efficient gene editing.

Scribe Therapeutics Inc. Fundamentals Summary

How do Scribe Therapeutics's earnings and revenue compare to its market cap?
SCTX fundamental statistics
Market cap	US$226.55m
Earnings (TTM)	-US$35.73m
Revenue (TTM)	US$36.28m

6.2x

P/S Ratio

-6.3x

P/E Ratio

Is SCTX overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
SCTX income statement (TTM)
Revenue	US$36.28m
Cost of Revenue	US$56.11m
Gross Profit	-US$19.83m
Other Expenses	US$15.90m
Earnings	-US$35.73m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)	-2.21
Gross Margin	-54.65%
Net Profit Margin	-98.48%
Debt/Equity Ratio	-105.6%

How did SCTX perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

Data	Last Updated (UTC time)
Company Analysis	2026/07/24 06:13
End of Day Share Price	2026/07/23 00:00
Earnings	2026/03/31
Annual Earnings	2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

Package	Data	Timeframe	Example US Source ^*
Company Financials	10 years	Income statement Cash flow statement Balance sheet	SEC Form 10-K SEC Form 10-Q
Analyst Consensus Estimates	+3 years	Forecast financials Analyst price targets	Analyst Research Reports Blue Matrix
Market Prices	30 years	Stock prices Dividends, Splits and Actions	ICE Market Data SEC Form S-1
Ownership	10 years	Top shareholders Insider trading	SEC Form 4 SEC Form 13D
Management	10 years	Leadership team Board of directors	SEC Form 10-K SEC Form DEF 14A
Key Developments	10 years	Company announcements	SEC Form 8-K

^* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Scribe Therapeutics Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

Scribe Therapeutics Inc.NasdaqGM:SCTX Stock Report